Opevesostat

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameOpevesostat
Drug Alias NameODM-208MK-5684
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytochrome P450 11A1 inhibitors
TargetsCytochrome P450 11A1
Therapy Area/IndicationsKidney Failure, ChronicHepatic InsufficiencyNeoplasm Metastasis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[46] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesOrion Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme LLCOrion Corporation Orion PharmaMSD R&D（China）Co Ltd
Inactive CompaniesN/A
Active IndicationsKidney Failure, ChronicHepatic InsufficiencyNeoplasm Metastasis +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A